Myriad Genetics And 2 Other Penny Stocks To Watch Closely

The United States market has shown robust growth, rising 3.5% over the last week and 31% over the past year, with earnings expected to increase by 16% annually in the coming years. In such a thriving market, identifying stocks with strong financials becomes crucial for investors seeking both affordability and growth potential. Although often considered a term from bygone eras, penny stocks continue to offer intriguing opportunities within smaller or newer companies that might surprise investors with their value and stability.

Top 10 Penny Stocks In The United States

Name Share Price Market Cap Financial Health Rating ATRenew (RERE) $4.42 $987.04M ★★★★★★ LexinFintech Holdings (LX) $2.25 $378.59M ★★★★★★ Tuya (TUYA) $2.34 $1.41B ★★★★★★ FinVolution Group (FINV) $4.94 $1.25B ★★★★★☆ Tuniu (TOUR) $0.7333 $85.08M ★★★★★★ Information Services Group (III) $3.11 $188.79M ★★★★★★ Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ★★★★★★ Niagen Bioscience (NAGE) $4.38 $351.48M ★★★★★★ Cricut (CRCT) $4.00 $847.13M ★★★★★★ LifeVantage (LFVN) $4.25 $54.42M ★★★★★★

Click here to see the full list of 360 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Myriad Genetics

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops molecular tests, with a market cap of approximately $444.16 million.

Operations: The company generates revenue of $824.5 million from its biotechnology segment.

Market Cap: $444.16M

Myriad Genetics, Inc., with a market cap of US$444.16 million, has faced challenges such as being dropped from major indices like the S&P 1000 and S&P 600 but remains active in product innovation. Recent FDA approval for its MyChoice CDx Test as a companion diagnostic for Zejula highlights its role in precision medicine. Despite unprofitability and increasing losses over five years, Myriad maintains a strong cash position exceeding debt levels, providing a runway of over three years. The company continues to expand its molecular diagnostics offerings with the launch of tests like Precise MRD for cancer monitoring.

Get an in-depth perspective on Myriad Genetics' performance by reading our balance sheet health report here. Evaluate Myriad Genetics' prospects by accessing our earnings growth report.MYGN Debt to Equity History and Analysis as at Apr 2026

Prelude Therapeutics

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing novel cancer medicines for underserved patients, with a market cap of $285.57 million.

Story Continues

Operations: The company generates revenue from its Biotechnology (Startups) segment, amounting to $12.14 million.

Market Cap: $285.57M

Prelude Therapeutics, with a market cap of US$285.57 million, remains focused on developing innovative cancer treatments despite being unprofitable and experiencing increased losses over the past five years. The company reported revenue of US$12.14 million in 2025 and has recently made strides with its KAT6A degrader program, presenting promising preclinical data at the AACR Annual Meeting 2026. Prelude also received FDA clearance to initiate a Phase 1 study for its JAK2V617F inhibitor aimed at treating myeloproliferative neoplasms. With no debt and sufficient cash runway exceeding one year, Prelude continues to advance its clinical pipeline amid high share price volatility.

Click here and access our complete financial health analysis report to understand the dynamics of Prelude Therapeutics. Assess Prelude Therapeutics' future earnings estimates with our detailed growth reports.PRLD Revenue & Expenses Breakdown as at Apr 2026

ThredUp

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: ThredUp Inc. operates an online resale platform in the United States and has a market cap of approximately $426.84 million.

Operations: ThredUp generates revenue from its online retail segment, which amounted to $310.81 million.

Market Cap: $426.84M

ThredUp Inc., with a market cap of US$426.84 million, has shown revenue growth, reporting US$310.81 million in 2025 and projecting further increases in 2026. Despite being unprofitable, the company reduced its net loss significantly over the past year and maintains a strong cash position relative to its debt obligations. The management team is experienced, which may contribute to strategic financial decisions such as reducing debt levels from 134.3% to 30.7% over five years and extending loan maturities. However, ThredUp's share price remains highly volatile, reflecting broader challenges within the specialty retail sector for penny stocks.

Dive into the specifics of ThredUp here with our thorough balance sheet health report. Understand ThredUp's earnings outlook by examining our growth report.TDUP Debt to Equity History and Analysis as at Apr 2026

Taking Advantage

Explore the 360 names from our US Penny Stocks screener here. Want To Explore Some Alternatives? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MYGNPRLD and TDUP.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments